SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbi ...